Add Yahoo as a preferred source to see more of our stories on Google. On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...

In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...

This post was co-authored by Shontae Cameron, and Robert T. Muller, Ph.D. The World Health Organization estimates that schizophrenia affects around 24 million people, or roughly 1 in 300 individuals ...

Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscience Data show TEV-'749 drug delivery technology ...

Schizophrenia is a chronic, severe, and disabling brain disorder that is caused by alterations in neurodevelopmental and neurodegenerative brain function. The results affect many parts of your life ...

Sexual dysfunction is a common side effect of antipsychotics, but it doesn’t have to be permanent. Learn about causes, ...

A free community lecture by a national expert on schizophrenia treatment will be held from 8 a.m. to noon on Dec. 10 at Peak Vista Community Health Centers, 2828 International Circle, Suite 120, in ...

Neurocrine Biosciences Inc. plunged early Wednesday after a study of its experimental schizophrenia treatment was disappointing when compared to a rival medicine that’s likely to hit the market much ...